Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

890820C

Avanti

18:0 DAP

Avanti Polar Lipids 890820C

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
1,2-distearoyl-3-dimethylammonium-propane
Empirical Formula (Hill Notation):
C41H81NO4
CAS Number:
121315-93-3
Molecular Weight:
652.09
UNSPSC Code:
12352211
NACRES:
NA.25

form

liquid

packaging

pkg of 1 × 2.5 mL (890820C-25mg)

manufacturer/tradename

Avanti Polar Lipids 890820C

concentration

10 mg/mL (890820C-25mg)

lipid type

transfection
cationic lipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H]C(CN(C)C)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O

Application

1,2-distearoyl-3-dimethylammonium-propane (18:0 DAP) might be used to formulate lipid nanoparticles (LNPs) and to test its efficiency of packaging mRNA into an LNP. It might also be used in the preparation of “bubble liposomes” (BLs).

Biochem/physiol Actions

1,2-distearoyl-3-dimethylammonium-propane (18:0 DAP) is a cationic lipid and serves as a pH-sensitive transfection reagent.

Packaging

5 mL Clear Glass Sealed Ampule (890820C-25mg)

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Target Organs

Central nervous system

WGK

WGK 3

Regulatory Information

易制毒化学品（2类）
危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoko Endo-Takahashi et al.
Biomaterials, 34(11), 2807-2813 (2013-01-25)
We have developed polyethyleneglycol (PEG)-modified liposomes (Bubble liposomes; BLs) that entrap ultrasound (US) contrast gas, and we have reported that the combination of BLs and US exposure was an effective tool for delivering pDNA and siRNA in vitro and in
Siddharth Patel et al.
Journal of controlled release : official journal of the Controlled Release Society, 303, 91-100 (2019-04-16)
Retinal gene therapy has had unprecedented success in generating treatments that can halt vision loss. However, immunogenic response and long-term toxicity with the use of viral vectors remain a concern. Non-viral vectors are relatively non-immunogenic, scalable platforms that have had

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service